A detailed history of Cormorant Asset Management, LP transactions in Pharvaris N.V. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 1,466,460 shares of PHVS stock, worth $29.8 Million. This represents 1.9% of its overall portfolio holdings.

Number of Shares
1,466,460
Previous 1,466,460 -0.0%
Holding current value
$29.8 Million
Previous $27.6 Million 1.49%
% of portfolio
1.9%
Previous 2.12%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$15.67 - $24.59 $3.84 Million - $6.02 Million
-245,000 Reduced 14.32%
1,466,460 $27.6 Million
Q4 2023

Feb 14, 2024

BUY
$15.2 - $28.05 $5.32 Million - $9.82 Million
350,000 Added 25.71%
1,711,460 $48 Million
Q3 2023

Nov 14, 2023

BUY
$14.68 - $21.4 $5.69 Million - $8.3 Million
387,846 Added 39.84%
1,361,460 $28.4 Million
Q2 2023

Aug 14, 2023

BUY
$7.82 - $16.0 $1.23 Million - $2.51 Million
157,154 Added 19.25%
973,614 $14.7 Million
Q4 2022

Feb 14, 2023

SELL
$1.98 - $11.46 $774,259 - $4.48 Million
-391,040 Reduced 32.38%
816,460 $9.19 Million
Q3 2022

Nov 14, 2022

BUY
$7.67 - $25.8 $472,065 - $1.59 Million
61,547 Added 5.37%
1,207,500 $9.26 Million
Q2 2022

Aug 15, 2022

BUY
$16.35 - $27.5 $7.54 Million - $12.7 Million
461,065 Added 67.32%
1,145,953 $25.3 Million
Q1 2022

May 16, 2022

SELL
$15.98 - $19.65 $77,391 - $95,164
-4,843 Reduced 0.7%
684,888 $12.4 Million
Q3 2021

Nov 15, 2021

SELL
$13.14 - $20.97 $724,434 - $1.16 Million
-55,132 Reduced 7.4%
689,731 $12.2 Million
Q2 2021

Aug 16, 2021

SELL
$18.05 - $29.59 $2.15 Million - $3.53 Million
-119,280 Reduced 13.8%
744,863 $13.6 Million
Q1 2021

May 17, 2021

BUY
$25.25 - $40.11 $21.8 Million - $34.7 Million
864,143 New
864,143 $23.8 Million

Others Institutions Holding PHVS

About Pharvaris N.V.


  • Ticker PHVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,766,000
  • Market Cap $687M
  • Description
  • Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...
More about PHVS
Track This Portfolio

Track Cormorant Asset Management, LP Portfolio

Follow Cormorant Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.